EA201990738A1 - Соединения-ингибиторы бета-лактамаз - Google Patents

Соединения-ингибиторы бета-лактамаз

Info

Publication number
EA201990738A1
EA201990738A1 EA201990738A EA201990738A EA201990738A1 EA 201990738 A1 EA201990738 A1 EA 201990738A1 EA 201990738 A EA201990738 A EA 201990738A EA 201990738 A EA201990738 A EA 201990738A EA 201990738 A1 EA201990738 A1 EA 201990738A1
Authority
EA
Eurasian Patent Office
Prior art keywords
beta
compounds
inhibitor compounds
lactamase inhibitor
pharmaceutically acceptable
Prior art date
Application number
EA201990738A
Other languages
English (en)
Other versions
EA037916B1 (ru
Inventor
Жанель Комита-Превуар
Тома Франсуа Дюран-Ревий
Лиз Готье
Джон О'Доннелл
Ян Ромеро
Рубен Томмаси
Ерун Кюнера Верхейен
Франк У
Сяоюнь У
Цзин Чжан
Грегори С. Басараб
Билл Мосс
Original Assignee
Энтасис Терапеутикс Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Энтасис Терапеутикс Лимитед filed Critical Энтасис Терапеутикс Лимитед
Priority claimed from PCT/US2017/051692 external-priority patent/WO2018053215A1/en
Publication of EA201990738A1 publication Critical patent/EA201990738A1/ru
Publication of EA037916B1 publication Critical patent/EA037916B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Настоящее изобретение относится к соединениям, представляющим собой ингибиторы бета-лактамаз. Указанные соединения и их фармацевтически приемлемые соли в комбинации с бета-лактамными антибиотиками пригодны для лечения бактериальных инфекций, включая инфекции, вызванные организмами, устойчивыми к лекарственным средствам, включая организмы с множественной лекарственной устойчивостью. Настоящее изобретение включает соединения формулы (I)или их фармацевтически приемлемую соль, где значения R, R, R, R, Rи Rописаны в настоящем документе.
EA201990738A 2017-02-08 2017-09-15 Соединения-ингибиторы бета-лактамаз EA037916B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762456423P 2017-02-08 2017-02-08
PCT/US2017/051692 WO2018053215A1 (en) 2016-09-16 2017-09-15 Beta-lactamase inhibitor compounds

Publications (2)

Publication Number Publication Date
EA201990738A1 true EA201990738A1 (ru) 2019-08-30
EA037916B1 EA037916B1 (ru) 2021-06-07

Family

ID=67734930

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201990738A EA037916B1 (ru) 2017-02-08 2017-09-15 Соединения-ингибиторы бета-лактамаз
EA202190617A EA202190617A3 (ru) 2017-02-08 2017-09-15 Соединения-ингибиторы бета-лактамаз

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA202190617A EA202190617A3 (ru) 2017-02-08 2017-09-15 Соединения-ингибиторы бета-лактамаз

Country Status (1)

Country Link
EA (2) EA037916B1 (ru)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2825705B1 (fr) * 2001-06-08 2005-05-20 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens
FR2930553B1 (fr) * 2008-04-29 2010-05-21 Novexel Composes azabicycliques, leur preparation et leur utilisation comme medicaments, notamment inhibiteurs de beta-lactamases
JP5666743B2 (ja) * 2011-08-27 2015-02-12 ウォックハート リミテッド １，６−ジアザビシクロ［３，２，１］オクタン−７−オン誘導体および細菌感染の処置におけるそれらの使用
AR090539A1 (es) * 2012-04-02 2014-11-19 Astrazeneca Ab COMPUESTOS INHIBIDORES DE b LACTAMASA
RS58429B1 (sr) * 2014-11-17 2019-04-30 Entasis Therapeutics Ltd Kombinovana terapija za lečenje rezistentnih bakterijskih infekcija

Also Published As

Publication number Publication date
EA202190617A3 (ru) 2021-10-29
EA037916B1 (ru) 2021-06-07
EA202190617A2 (ru) 2021-06-30

Similar Documents

Publication Publication Date Title
PH12019500558A1 (en) Beta-lactamase inhibitor compounds
CY1124086T1 (el) Παραγωγα 3-τετραζολυλ-βενζεν-1,2-δισουλφοναμιδιου ως αναστολεις μεταλλο-βητα-λακταμασης
CY1120269T1 (el) Ετεροδικυκλικες ενωσεις ως αναστολεις βητα-λακταμασης
CY1121701T1 (el) Οργανικες ενωσεις μονοβακταμης για την αντιμετωπιση βακτηριακων λοιμωξεων
EA201991523A1 (ru) Комбинированная терапия амидин-замещенными бета-лактамными соединениями и ингибиторами бета-лактамазы при инфекциях, вызванных бактериальными штаммами, резистентными к антибиотикам
BR112017010132A2 (pt) terapia combinada para tratamento de infecções bacterianas resistentes
NZ617104A (en) Pharmaceutical compositions comprising beta-lactam antibiotic, sulbactam and beta-lactamase inhibitor
EA202090604A1 (ru) Хроманмонобактамовые соединения для лечения бактериальных инфекций
BR112018074985A2 (pt) composições antibacterianas
CY1123062T1 (el) Αναστολεις βητα-λακταμασης
EA201992370A1 (ru) Соединения и способы для лечения бактериальных инфекций
EA201990738A1 (ru) Соединения-ингибиторы бета-лактамаз
CY1119316T1 (el) Υδροχλωρικα αλατα μιας αντιβιοτικης ενωσης
EA202190444A1 (ru) Диазабициклооктаноны в качестве ингибиторов сериновых бета-лактамаз
EA202190585A1 (ru) Производные индана для применения при лечении бактериальной инфекции
EA202090357A1 (ru) Химические соединения
TH1701007800A (th) ตัวยับยั้งเมทัลโล-บีตา-แลคทาเมส